(Q37694429)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Bruce C Baguley

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1859-1871

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166210%20AND%20SRC:MED&resulttype=core&format=json

Studies in tissue metabolism: The action of colchicine and B. typhosus extract

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Factors determining the action of colchicine on tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

The development of combretastatin A4 phosphate as a vascular targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

21 January 2018

Vascular damaging agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular Endothelium as the Vulnerable Element in Tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular attack as a therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The current status and evolving role of sunitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The discovery of antiangiogenic molecules: a historical review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Targeting angiogenesis in the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Disrupting tumour blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Antivascular therapy of cancer: DMXAA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular-targeting therapies for treatment of malignant disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Vascular targeting agents as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Rho GTPases and the regulation of endothelial permeability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Potential of DMXAA combination therapy for solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Quantitative vascularity of breast masses by Doppler imaging: regional variations and diagnostic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24975

7 January 2021